158 related articles for article (PubMed ID: 38294118)
1. Treatment Outcome of Severe Respiratory Type B Tularemia Using Fluoroquinolones.
Widerström M; Mörtberg S; Magnusson M; Fjällström P; Johansson AF
Clin Infect Dis; 2024 Jan; 78(Suppl 1):S38-S46. PubMed ID: 38294118
[TBL] [Abstract][Full Text] [Related]
2. Targeting Tularemia: Clinical, Laboratory, and Treatment Outcomes From an 11-year Retrospective Observational Cohort in Northern Sweden.
Plymoth M; Lundqvist R; Nystedt A; Sjöstedt A; Gustafsson TN
Clin Infect Dis; 2024 May; 78(5):1222-1231. PubMed ID: 38393822
[TBL] [Abstract][Full Text] [Related]
3. Consequences of delayed ciprofloxacin and doxycycline treatment regimens against Francisella tularensis airway infection.
Rotem S; Bar-Haim E; Cohen H; Elia U; Ber R; Shafferman A; Cohen O
Antimicrob Agents Chemother; 2012 Oct; 56(10):5406-8. PubMed ID: 22850512
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Doxycycline and Ciprofloxacin for Treatment of Pneumonic Tularemia in Cynomolgus Macaques.
Williams MS
Clin Infect Dis; 2024 Jan; 78(Suppl 1):S7-S14. PubMed ID: 38294111
[TBL] [Abstract][Full Text] [Related]
5. [Mediastinal lymphadenopathy: Do not forget tularemia!].
Tissot N; Noureddine S; Guion-Dusserre M; Soumagne T
Rev Mal Respir; 2021 Feb; 38(2):204-209. PubMed ID: 33581986
[TBL] [Abstract][Full Text] [Related]
6. Antibiotic susceptibility of Francisella tularensis subsp. holarctica strains isolated from tularaemia patients in France between 2006 and 2016.
Caspar Y; Hennebique A; Maurin M
J Antimicrob Chemother; 2018 Mar; 73(3):687-691. PubMed ID: 29253157
[TBL] [Abstract][Full Text] [Related]
7. Case Report of Low Virulence Francisella tularensis Presented as Severe Bacteremic Pneumonia.
Su TY; Shie SS; Chia JH; Huang CT
Medicine (Baltimore); 2016 May; 95(19):e3390. PubMed ID: 27175638
[TBL] [Abstract][Full Text] [Related]
8. Treatment of tularemia in patient with chronic graft-versus-host disease.
Weile J; Seibold E; Knabbe C; Kaufmann M; Splettstoesser W
Emerg Infect Dis; 2013 May; 19(5):771-3. PubMed ID: 23647853
[TBL] [Abstract][Full Text] [Related]
9. Two cases of tick-borne transmitted tularemia on Southern Zealand, Denmark.
Haulrig MB; Mathiasen G; Nielsen RM; Kromann CB; Krogfelt KA; Wiese L
APMIS; 2020 Jan; 128(1):61-64. PubMed ID: 31691353
[TBL] [Abstract][Full Text] [Related]
10. A case report of ulceroglandular tularemia caused by Francisella tularensis subsp. Holarctica in Iran.
Esmaeili S; Ghasemi A; Esmaeili P; Rezaie F; Mohraz M; Maurin M; Mostafavi E
Acta Trop; 2022 Oct; 234():106570. PubMed ID: 35752204
[TBL] [Abstract][Full Text] [Related]
11. Treatment of tularemia with ciprofloxacin.
Scheel O; Reiersen R; Hoel T
Eur J Clin Microbiol Infect Dis; 1992 May; 11(5):447-8. PubMed ID: 1425715
[TBL] [Abstract][Full Text] [Related]
12. [In Vitro Activity of Tigecycline Against Francisella tularensis Subsp. holarctica in Comparison with Doxycycline, Ciprofloxacin and Aminoglycosides].
Ulu Kılıç A; Kılıç S; Celebi B; Sencan I
Mikrobiyol Bul; 2013 Jan; 47(1):189-91. PubMed ID: 23390918
[TBL] [Abstract][Full Text] [Related]
13. Tularemia Clinical Manifestations, Antimicrobial Treatment, and Outcomes: An Analysis of US Surveillance Data, 2006-2021.
Wu HJ; Bostic TD; Horiuchi K; Kugeler KJ; Mead PS; Nelson CA
Clin Infect Dis; 2024 Jan; 78(Suppl 1):S29-S37. PubMed ID: 38294115
[TBL] [Abstract][Full Text] [Related]
14. Epidemiological and clinical characteristics and management of oropharyngeal tularemia outbreak.
Uzun MÖ; Yanik K; Erdem M; Kostakoglu U; Yilmaz G; Tanriverdi Çayci Y
Turk J Med Sci; 2015; 45(4):902-6. PubMed ID: 26422865
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial Susceptibility of Francisella tularensis Isolates in the United States, 2009-2018.
Choat J; Young J; Petersen JM; Dietrich EA
Clin Infect Dis; 2024 Jan; 78(Suppl 1):S4-S6. PubMed ID: 38294116
[TBL] [Abstract][Full Text] [Related]
16. In vitro susceptibility of Francisella tularensis to fluoroquinolones and treatment of tularemia with norfloxacin and ciprofloxacin.
Syrjälä H; Schildt R; Räisäinen S
Eur J Clin Microbiol Infect Dis; 1991 Feb; 10(2):68-70. PubMed ID: 1864276
[TBL] [Abstract][Full Text] [Related]
17.
Caspar Y; Maurin M
Front Cell Infect Microbiol; 2017; 7():122. PubMed ID: 28443249
[TBL] [Abstract][Full Text] [Related]
18. In vitro susceptibility of isolates of Francisella tularensis from Turkey.
Kiliç S; Celebi B; Acar B; Ataş M
Scand J Infect Dis; 2013 May; 45(5):337-41. PubMed ID: 23249114
[TBL] [Abstract][Full Text] [Related]
19. Treatment of murine pneumonic Francisella tularensis infection with gatifloxacin, moxifloxacin or ciprofloxacin.
Steward J; Piercy T; Lever MS; Simpson AJ; Brooks TJ
Int J Antimicrob Agents; 2006 May; 27(5):439-43. PubMed ID: 16621457
[TBL] [Abstract][Full Text] [Related]
20. Streptomycin and alternative agents for the treatment of tularemia: review of the literature.
Enderlin G; Morales L; Jacobs RF; Cross JT
Clin Infect Dis; 1994 Jul; 19(1):42-7. PubMed ID: 7948556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
